#4A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	**ART UNIT: 1704**
	)	Conf. No.: 4070
LEY et al	)	Examiner:
	)	
Appln. No.: 10/038,722	)	Washington, D.C.
	)	
Filed: January 8, 2002	)	June 7, 2002
	)	
For: ITI-D1 KUNITZ DOMAIN MUTANTS AS hNE INHIBITORS	)	Atty.Docket: LEY=1B
	)	

RESPONSE TO "SEQUENCE LISTING" REQUIREMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply, mailed April 10, 2002, please amend the application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at line 6 of page 25 with the following rewritten paragraph:

A1

We assume that ITI-D1 and EpiNE-7 have the same 3D configuration in solution as BPTI. Although EpiNE-7 and ITI-D1 are identical at positions 13, 17, 20, 32, and 39, they differ greatly in their affinities for hNE. To improve the affinity of ITI-D1 for hNE, the EpiNE-7 sequence **Val**$_{15}$-**Ala**$_{16}$-Met$_{17}$-**Phe**$_{18}$-**Pro**$_{19}$-Arg$_{20}$ (of SEQ ID NO:9) (**bold**, underscored amino acids are alterations) was incorporated into the ITI-D1 sequence by cassette mutagenesis between the *Eag*I and